Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

  • Dirk Eyding
  • Monika Lelgemann
  • Ulrich Grouven
  • Martin Härter
  • Mandy Kromp
  • Thomas Kaiser
  • Michaela F Kerekes
  • Martin Gerken
  • Beate Wieseler

Abstract

To assess the benefits and harms of reboxetine versus placebo or selective serotonin reuptake inhibitors (SSRIs) in the acute treatment of depression, and to measure the impact of potential publication bias in trials of reboxetine.

Bibliografische Daten

OriginalspracheDeutsch
ISSN0959-535X
StatusVeröffentlicht - 2010
pubmed 20940209